共 97 条
XPC multifaceted roles beyond DNA damage repair: p53-dependent and p53-independent functions of XPC in cell fate decisions
被引:8
作者:
Zebian, Abir
[1
,2
]
El-Dor, Maya
[2
]
Shaito, Abdullah
[3
]
Mazurier, Frederic
[4
]
Rezvani, Hamid Reza
[4
]
Zibara, Kazem
[2
,5
]
机构:
[1] Univ Bordeaux, BMGIC, INSERM U1035, Bordeaux, France
[2] Lebanese Univ, PRASE, Beirut, Lebanon
[3] Qatar Univ, Biomed Res Ctr, POB 2713, Doha, Qatar
[4] Univ Rennes 1, CNRS, UMR 6290, IGDR, F-35000 Rennes, France
[5] Lebanese Univ, Fac Sci 1, Biol Dept, Beirut, Lebanon
关键词:
XPC;
DNA repair;
DNA damage response;
Cell fate;
p53;
Tumor suppressor;
NUCLEOTIDE EXCISION-REPAIR;
CYCLOBUTANE PYRIMIDINE DIMERS;
GLOBAL GENOMIC REPAIR;
XERODERMA-PIGMENTOSUM;
INDUCED APOPTOSIS;
TUMOR-SUPPRESSOR;
UV-IRRADIATION;
P53;
REGULATION;
GLIOMA-CELLS;
GENE;
D O I:
10.1016/j.mrrev.2021.108400
中图分类号:
Q81 [生物工程学(生物技术)];
Q93 [微生物学];
学科分类号:
071005 ;
0836 ;
090102 ;
100705 ;
摘要:
Xeroderma pigmentosum group C protein (XPC) acts as a DNA damage recognition factor for bulky adducts and as an initiator of global genome nucleotide excision repair (GG-NER). Novel insights have shown that the role of XPC is not limited to NER, but is also implicated in DNA damage response (DDR), as well as in cell fate decisions upon stress. Moreover, XPC has a proteolytic role through its interaction with p53 and casp-2S. XPC is also able to determine cellular outcomes through its interaction with downstream proteins, such as p21, ARF, and p16. XPC interactions with effector proteins may drive cells to various fates such as apoptosis, senescence, or tumorigenesis. In this review, we explore XPC's involvement in different molecular pathways in the cell and suggest that XPC can be considered not only as a genomic caretaker and gatekeeper but also as a tumor suppressor and cellular-fate decision maker. These findings envisage that resistance to cell death, induced by DNA damaging therapeutics, in highly prevalent P53-deficent tumors might be overcome through new therapeutic approaches that aim to activate XPC in these tumors. Moreover, this review encourages care providers to consider XPC status in cancer patients before chemotherapy in order to improve the chances of successful treatment and enhance patients' survival.
引用
收藏
页数:9
相关论文